Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1
|
作者：
Calvo Romero, J. M. [1 ]
机构：
[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain
来源：
REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期
关键词：
Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;
D O I：
10.1016/j.rce.2010.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：142 / 146
页数：5
相关论文
共 50 条
  • [31] Dabigatran (Pradaxa) for Prevention of Stroke in Atrial Fibrillation
    Strohecker, Jennifer L.
    AMERICAN FAMILY PHYSICIAN, 2011, 84 (12) : 1397 - 1398
  • [32] Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
    Schaefer, Andreas
    Flierl, Ulrike
    Berliner, Dominik
    Bauersachs, Johann
    CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (04) : 555 - 568
  • [33] Dabigatran in real-world atrial fibrillation Meta-analysis of observational comparison studies with vitamin K antagonists
    Carmo, Joao
    Costa, Francisco Moscoso
    Ferreira, Jorge
    Mendes, Miguel
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (04) : 754 - 763
  • [34] Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter
    Kaiser, Daniel W.
    Streur, Megan M.
    Nagarakanti, Rangadham
    Whalen, S. Patrick
    Ellis, Christopher R.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2013, 37 (03) : 241 - 247
  • [35] Novel anticoagulants for stroke prevention in atrial fibrillation
    Baumhaekel, M.
    Schirmer, S. H.
    Boehm, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (46) : 2304 - 2308
  • [36] Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
    DiNicolantonio, James J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1101 - 1111
  • [37] Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation? A Critically Appraised Topic
    Adcock, Amelia K.
    Lee-Iannotti, Joyce K.
    Aguilar, Maria I.
    Hoffman-Snyder, Charlene R.
    Wingerchuk, Dean M.
    Wellik, Kay E.
    Demaerschalk, Bart M.
    NEUROLOGIST, 2012, 18 (02) : 102 - 107
  • [38] Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
    Clemens, Andreas
    Haertter, Sebastian
    Friedman, Jeffrey
    Brueckmann, Martina
    Stangier, Joachim
    van Ryn, Joanne
    Lehr, Thorsten
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 195 - 201
  • [39] Feasibility and Safety of Uninterrupted Dabigatran Therapy in Patients Undergoing Ablation for Atrial Fibrillation
    Nagao, Tomoyuki
    Inden, Yasuya
    Shimano, Masayuki
    Fujita, Masaya
    Yanagisawa, Satoshi
    Kato, Hiroyuki
    Ishikawa, Shinji
    Miyoshi, Aya
    Okumura, Satoshi
    Ohguchi, Shiou
    Yamamoto, Toshihiko
    Yoshida, Naoki
    Hirai, Makoto
    Murohara, Toyoaki
    INTERNAL MEDICINE, 2015, 54 (10) : 1167 - 1173
  • [40] Dabigatran Etexilate A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    McKeage, Kate
    PHARMACOECONOMICS, 2012, 30 (09) : 841 - 855
12345